Table 1.
Clinical data of the 17 patients with PGS.
| Case | Age | Sex | Clinical presentation | Surgical resection | KPS | Radiotherapy | TMZ | Time to progression (months) | Surgical re-intervention | 2nd Line chemotherapy | Overall survival (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 56 | M | Focal deficit | Near total | 100 | External beam | + | 7 | + | PCV | 12 |
| 2 | 61 | M | Focal deficit; ICH | Near total | 100 | External beam | + | 5 | − | − | 8 |
| 3 | 71 | M | Focal deficit | Near total | 90 | External beam | + | 4 | − | − | 5 |
| 4 | 59 | M | Focal deficit | Near total | 100 | External beam | + | 3 | + | − | 11 |
| 5 | 60 | F | ICH | Near total | 90 | External beam | + | 7 | + | PCV | 13 |
| 6 | 63 | M | Focal deficit | Near total | 70 | External beam | + | 5 | + | BCV | 31 |
| 7 | 52 | M | Focal deficit; ICH | Near total | 90 | External beam | + | 6 | − | BCV | 15 |
| 8 | 62 | M | Impaired consciousness | Near total | 30 | − | − | 1 | − | − | 4 |
| 9 | 64 | F | Focal deficit | Near total | 60 | External beam | + | 9 | − | PCV | 12 |
| 10 | 64 | F | Focal deficit | Near total | 90 | External beam | + | 6 | − | BCV | 8 |
| 11 | 59 | F | ICH | Near total | 100 | External beam | + | 3 | + | − | 5 |
| 12 | 74 | F | ICH | Near total | 70 | − | a | 1 | − | − | 11 |
| 13 | 27 | F | Seizures, ICH Focal deficit | Total | 100 | External beam | + | 2 | + | − | 45+(alive) |
| 14 | 63 | F | Focal deficit | Near total | 90 | External beam | + | 12 | + | BCV | 18+(alive) |
| 15 | 66 | F | Focal deficit | Near total | 80 | External beam | + | 5 | − | BCV | 14 |
| 16 | 49 | F | Focal deficit | Near total | 70 | External beam | + | 2 | − | − | 6 |
| 17 | 52 | F | ICH | Total | 90 | External beam | b | 9 | + | BCV | 18 |
ICH: intracranial hypertension; KPS: Karnofsky performance score; TMZ: temozolomide; PCV: procarbazine, lomustine and vincristine; BCV: bevacizumab; a: only temozolomide; b: only 3 cycles of temozolomide.